Author: Teresa Sellinger

Several studies were presented at the 2024 Crohn’s & Colitis Congress, covering the impacts on IBD of malnutrition, dietary supplements, and various diets.

Patient-reported outcomes on HRQOL in psoriasis are limited and require additional validation to properly assess individuals with the condition.

Research from ASH 2023 showed standard treatment options lack efficacy for patients who are positive for the TP53 mutation with AML.

At Maui Derm Hawaii, Joel Gelfand, MD, MSCE, presented as part of “Challenging Cases in Psoriasis.” He published 2 related papers recently, which we summarize.

Bruce Strober, MD, PhD, published a paper recently in JAMA Dermatol focusing on disease burden measurements of meaning to patients with psoriasis.

At Maui Derm Hawaii, Andrew Blauvelt, MD, MBA, presented as part of “Psoriasis Update: 2024.” Here, we summarize a paper he published in this area of study.

At Maui Derm Hawaii, held January 22-26, 2024, Linda Stein-Gold, MD, presented as part of “Challenging Cases in Psoriasis.”

Social determinants of health influenced the achievement of textbook oncological outcomes and overall survival in non-small cell lung cancer.

Lymphovascular invasion is an independent predictor for shorter recurrence-free survival for patients with stage I NSCLC.